Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adagene (ADAG)
NASDAQ:ADAG
Holding ADAG?
Track your performance easily
ADAG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.74 - $4.29
Previous CloseN/A
Volume1.51K
Average Volume (3M)128.16K
Market Cap
$85.44M
Enterprise Value$60.32M
Total Cash (Recent Filing)$49.06M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Mar 27, 2025EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding44,156,982
10 Day Avg. Volume267,029
30 Day Avg. Volume128,165
Standard Deviation0.23
R-Squared0.01
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.70
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.33
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.75Price Target Upside210.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Adagene News
PremiumCompany Announcements
Adagene Reports Promising Results in Colorectal Cancer Study
PremiumCompany Announcements
Adagene Unveils Promising Data for Cancer Therapy
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyThe combination of ADG126 and pembrolizumab achieved an overall response rate of 33% in patients with no liver and peritoneal metastases, showing significant improvement over previous cohorts.
Regulatory ApprovalExperts believe a drug delivering high response rates, along with maintaining repeat dosing and durable efficacy, is likely to receive FDA approval, potentially through an Accelerated Approval pathway.
Therapeutic PotentialADG126 presented positive data from its ongoing Phase 1/2 study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, solidifying its therapeutical potential in metastatic microsatellite stable colorectal cancer.
Bears Say
Development DelaysThe launch timeline of ADG126 has been pushed out from 2028 to 2029, reflecting uncertainty in its development plan.
Regulatory ChallengesThere is little clarity on the regulatory development path for ADG126 given the selective patient population.
Regulatory ComplexityThe complexity of regulatory discussions is increased due to the selected patient population and lack of clarity in the development plan for ADG126.
---
Ownership Overview
―
Insiders
0.02%
Mutual Funds
13.49% Other Institutional Investors
86.49% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ADAG FAQ
What was Adagene’s price range in the past 12 months?
Adagene lowest stock price was $1.74 and its highest was $4.29 in the past 12 months.
What is Adagene’s market cap?
Adagene’s market cap is $85.44M.
When is Adagene’s upcoming earnings report date?
Adagene’s upcoming earnings report date is Mar 27, 2025 which is in 55 days.
How were Adagene’s earnings last quarter?
Adagene released its earnings results on Jul 25, 2024. The company reported -$0.285 earnings per share for the quarter, beating the consensus estimate of -$0.41 by $0.125.
Is Adagene overvalued?
According to Wall Street analysts Adagene’s price is currently Undervalued.
Does Adagene pay dividends?
Adagene does not currently pay dividends.
What is Adagene’s EPS estimate?
Adagene’s EPS estimate is -0.47.
How many shares outstanding does Adagene have?
Adagene has 44,156,982 shares outstanding.
What happened to Adagene’s price movement after its last earnings report?
Adagene reported an EPS of -$0.285 in its last earnings report, beating expectations of -$0.41. Following the earnings report the stock price went down -0.395%.
Which hedge fund is a major shareholder of Adagene?
Currently, no hedge funds are holding shares in ADAG
---
Adagene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.75 (210.81% Upside)
$5.75 (210.81% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.73%
12-Months-Change
Fundamentals
Return on Equity
-46.16%
Trailing 12-Months
Asset Growth
-25.52%
Trailing 12-Months
Company Description
Adagene
Adagene Inc is a clinical-stage immunotherapy company focused on the design and discovery of antibodies for the treatment of cancer.
---
ADAG Stock 12 Month Forecast
Average Price Target
$5.75
▲(210.81% Upside)
Technical Analysis
Best Analysts Covering ADAG
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+20.52%
reiterated a buy rating 4 days ago
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +20.52% per trade.
---